Tags

Type your tag names separated by a space and hit enter

Novel experimental model of non-infectious pharyngitis in rats.
J Pharmacol Toxicol Methods 2014 Mar-Apr; 69(2):189-95JP

Abstract

INTRODUCTION

Currently, there is a paucity of scientific literature and reports related to screening models for non-infectious type of pharyngitis. In this context, we made a sincere attempt to establish a novel animal model for screening drugs against non-infectious pharyngitis in rats. We have considered the use of pyridine, croton oil and their combination for inducing non-infectious pharyngitis in rats.

METHODS

Various concentrations of pyridine were applied topically to the pharyngeal region of rats and the extent of inflammation was assessed by Evans Blue (EB) dye exudation test, evaluating the serum levels of proinflammatory cytokines and histopathology. Dexamethasone and diclofenac were used as reference standards.

RESULTS

Upon pyridine application (2.5%, 5%, 10%, 20%, 40% and 80% in saline), dose-dependent increase in EB dye extravasation was observed (increased vascular permeability). In addition, the levels of TNF-α (P<0.01) and IL-6 (P<0.01) were significantly increased compared to control. Furthermore, the histopathology of pharyngeal tissue showed hypertrophy of submucosal glands, severe inflammation of the pharynx characterised by presence of mononuclear cells, neutrophils along with haemorrhages and congestion; however, normal control animals showed normal cytoarchitecture of pharynx. Indeed, dexamethasone (0.25, 0.5 and 1 mg/kg, i.v.) and diclofenac (1, 2.5 and 5 mg/kg, i.v.) showed dose-dependent protection against pyridine-induced pharyngitis. Further, the possible mechanism of pyridine-induced pharyngitis is thought to be primarily mediated through phospholipase A2 and cyclooxygenase (COX) pathway.

CONCLUSION

These findings suggest that pyridine-induced pharyngitis is a simple and versatile novel animal model for screening the drugs against non-infectious pharyngitis in rats.

Authors+Show Affiliations

Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India. Electronic address: glv_000@yahoo.com.Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India.Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India. Electronic address: dr.rafiq@himalayahealthcare.com.Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India.Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India.Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India.Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India.Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India.Department of Pharmacology, R&D Center, The Himalaya Drug Company, Bangalore, Karnataka, India.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24333504

Citation

Viswanatha, G L., et al. "Novel Experimental Model of Non-infectious Pharyngitis in Rats." Journal of Pharmacological and Toxicological Methods, vol. 69, no. 2, 2014, pp. 189-95.
Viswanatha GL, Thippeswamy AH, Rafiq M, et al. Novel experimental model of non-infectious pharyngitis in rats. J Pharmacol Toxicol Methods. 2014;69(2):189-95.
Viswanatha, G. L., Thippeswamy, A. H., Rafiq, M., Jagadeesh, M., Baig, M. R., Suryakanth, D. A., ... Ramakrishnan, S. (2014). Novel experimental model of non-infectious pharyngitis in rats. Journal of Pharmacological and Toxicological Methods, 69(2), pp. 189-95. doi:10.1016/j.vascn.2013.12.001.
Viswanatha GL, et al. Novel Experimental Model of Non-infectious Pharyngitis in Rats. J Pharmacol Toxicol Methods. 2014;69(2):189-95. PubMed PMID: 24333504.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Novel experimental model of non-infectious pharyngitis in rats. AU - Viswanatha,G L, AU - Thippeswamy,A H M, AU - Rafiq,Mohamed, AU - Jagadeesh,M, AU - Baig,Mirza Rizwan, AU - Suryakanth,D A, AU - Azeemuddin,Mohammed, AU - Patki,P S, AU - Ramakrishnan,Shyam, Y1 - 2013/12/13/ PY - 2013/07/02/received PY - 2013/11/18/revised PY - 2013/12/02/accepted PY - 2013/12/17/entrez PY - 2013/12/18/pubmed PY - 2016/3/22/medline KW - Animal model KW - Chemically-induced pharyngitis KW - Dexamethasone (PubChem CID: 5743) KW - Diclofenac (PubChem CID: 3033) KW - Evans Blue (PubChem CID: 54599159) KW - Inflammation KW - Pharyngitis KW - Pyridine KW - Pyridine (PubChem CID: 1049) KW - Sore throat SP - 189 EP - 95 JF - Journal of pharmacological and toxicological methods JO - J Pharmacol Toxicol Methods VL - 69 IS - 2 N2 - INTRODUCTION: Currently, there is a paucity of scientific literature and reports related to screening models for non-infectious type of pharyngitis. In this context, we made a sincere attempt to establish a novel animal model for screening drugs against non-infectious pharyngitis in rats. We have considered the use of pyridine, croton oil and their combination for inducing non-infectious pharyngitis in rats. METHODS: Various concentrations of pyridine were applied topically to the pharyngeal region of rats and the extent of inflammation was assessed by Evans Blue (EB) dye exudation test, evaluating the serum levels of proinflammatory cytokines and histopathology. Dexamethasone and diclofenac were used as reference standards. RESULTS: Upon pyridine application (2.5%, 5%, 10%, 20%, 40% and 80% in saline), dose-dependent increase in EB dye extravasation was observed (increased vascular permeability). In addition, the levels of TNF-α (P<0.01) and IL-6 (P<0.01) were significantly increased compared to control. Furthermore, the histopathology of pharyngeal tissue showed hypertrophy of submucosal glands, severe inflammation of the pharynx characterised by presence of mononuclear cells, neutrophils along with haemorrhages and congestion; however, normal control animals showed normal cytoarchitecture of pharynx. Indeed, dexamethasone (0.25, 0.5 and 1 mg/kg, i.v.) and diclofenac (1, 2.5 and 5 mg/kg, i.v.) showed dose-dependent protection against pyridine-induced pharyngitis. Further, the possible mechanism of pyridine-induced pharyngitis is thought to be primarily mediated through phospholipase A2 and cyclooxygenase (COX) pathway. CONCLUSION: These findings suggest that pyridine-induced pharyngitis is a simple and versatile novel animal model for screening the drugs against non-infectious pharyngitis in rats. SN - 1873-488X UR - https://www.unboundmedicine.com/medline/citation/24333504/Novel_experimental_model_of_non_infectious_pharyngitis_in_rats_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1056-8719(13)00322-5 DB - PRIME DP - Unbound Medicine ER -